FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

52 letters match. Newest first.

  1. Stephen J. Fallon, Ph.D.

    FDA warns clinical investigator Stephen J. Fallon, Ph.D. over consent and record failures in an HIV self-test study.

    High risk
  2. Maria E. De La Torre Silva, M.D.

    Clinical investigator Dr. Maria E. De La Torre Silva enrolled a subject in two drug trials and kept inadequate study-drug records.

    Medium
  3. Pratik Doshi, M.D. / Alembic Pharmaceuticals Ltd.

    FDA warned investigator Dr. Pratik Doshi at Alembic's Vadodara site that a bioequivalence study consent form wrongly said nothing was experimental.

    High risk
  4. Jose M. Carpio, M.D.

    FDA warned clinical investigator Dr. Jose Carpio of Miami Lakes, FL, that trial subjects received less than the protocol-required dose of study drug.

    Medium
  5. Adnan Dahdul, MD

    FDA warns clinical investigator Dr. Adnan Dahdul over consent, eligibility and record failures in a biologics study.

    High risk
  6. Naseem A. Jaffrani, M.D.

    FDA says clinical investigator Dr. Naseem Jaffrani failed to report serious adverse events to sponsors within 24 hours in two drug trials.

    High risk
  7. Sourav K. Mishra, M.D. / All India Institute of Medical Sciences

    FDA warned clinical investigator Dr. Sourav K. Mishra at AIIMS Bhubaneswar over a doxorubicin liposome bioequivalence study that broke protocol and consent rules.

    High risk
  8. Mukesh B. Chandre, M.D., MBBS/Ashirwad Hospital & Research Centre

    FDA warned clinical investigator Dr. Mukesh Chandre over informed consent failures in a doxorubicin liposome bioequivalence study.

    High risk
  9. Ehsan Sadri, M.D.

    FDA warns Dr. Ehsan Sadri that two ineligible subjects received an investigational drug in clinical trials.

    High risk
  10. Bertrand P. Cole, D.O.

    FDA warns Dr. Bertrand P. Cole that he gave four trial subjects too much drug by not following the study plan.

    High risk
  11. Mark S. Dacey, M.D.

    FDA warns Dr. Mark S. Dacey that a trial subject underwent an optional eye-fluid sampling procedure after twice declining consent.

    High risk
  12. Prodrome Sciences USA, LLC

    Prodrome Sciences studied its supplement ProdromeNeuro Oil as a dementia drug in 29 people without first filing an IND, FDA says.

    High risk
  13. Purushothaman Damodara Kumaran, M.D. / Senthil Specialty Hospital

    FDA warned Senthil Specialty Hospital and Dr. Purushothaman Damodara Kumaran about missed safety monitoring in a bioequivalence study of an investigational drug.

    High risk
  14. Devalingam Mahalingam, M.D., Ph.D.

    FDA warns clinical investigator Devalingam Mahalingam, M.D., Ph.D. over a 100-fold investigational drug overdose that led to a subject's death.

    High risk
  15. Pamela K. Den Besten, DDS, MS

    Clinical Investigator (Sponsor)

  16. Ralph A. DeFronzo, M.D.

    Clinical Investigator/Sponsor

  17. Shirish M. Gadgeel, M.D.

    Clinical Investigator

  18. Mark J. Savant, M.D

    Clinical Investigator

  19. Peter Michael, M.D.

    Clinical Investigator

  20. American Behavioral Research Institute, LLC

    Clinical Investigator (Sponsor)

  21. Nana Barseghian, M.D.

    Clinical Investigator

  22. Americo F. Padilla, M.D.

    Clinical Investigator

  23. Mehran Michael Bahrami, M.D.

    Clinical Investigator

  24. ISOThrive, Inc.

    Clinical Investigator

  25. Han C. Phan, M.D.

    Clinical Investigator

  26. Richard W. Foltin, Ph.D.

    Clinical Investigator (Sponsor)

  27. Namita A. Goyal, M.D.

    Clinical Investigator

  28. Julio R. Flamini, M.D./Clinical Integrative Research Center of Atlanta

    Clinical Investigator

  29. Angela D. Ritter, M.D.

    Clinical Investigator (Sponsor)

  30. Kevin R. Bender, M.D./DBC Research Corporation

    Clinical Investigator

  31. Bret R. Rutherford, M.D.

    Clinical Investigator (Sponsor)

  32. Jeffrey W. Taub, M.D./Children's Hospital of Michigan

    Clinical Investigator

  33. Anish S. Shah, M.D./Siyan Clinical Research

    Clinical Investigator

  34. Melanie M. Hoppers, M.D./Physicians Quality Care

    Clinical Investigator

  35. Maria W. Greenwald, M.D.

    Clinical Investigator

  36. Antonio E. Blanco, M.D./Vista Health Research, LLC

    Clinical Investigator

  37. Luis Javier Pena-Hernandez, M.D., FCCP

    Clinical Investigator

  38. Angela M. Stupi, M.D.

    Clinical Investigator

  39. Randy J. Epstein, M.D./Chicago Cornea Consultants, Ltd.

    Clinical Investigator (Sponsor)

  40. Mobeen Mazhar, M.D.

    Investigational Device Exemptions (Clinical Investigator)

  41. Tyrone L. McCall, M.D./Cornea Associates of Texas

    Clinical Investigator (Sponsor)

  42. Maggie Jeffries, M.D. / Avanti Anesthesiology, LLC

    Clinical Investigator

  43. Adarsh Daswani, M.D.

    Clinical Investigator

  44. "David M. Lubeck, M.D./Arbor Centers for EyeCare

    Clinical Investigator (Sponsor)

  45. Smitha C. Reddy, M.D./ACRC Studies, LLC

    Clinical Investigator

  46. "Daniel C. Tarquinio, D.O./Center for Rare Neurological Diseases

    Clinical Investigator

  47. Sabine S. Hazan, M.D.

    Clinical Investigator (CI)

  48. Richard J. Obiso, PhD dba Avila Herbals, LLC

    Clinical Investigator

  49. Joseph A. Zadra, M.D.

    Clinical Investigator

  50. Evelyn Lopez-Brignoni, M.D.

    Clinical Investigator